XBiotech Inc.
XBIT evidence brief
What we can confirm
- Market Cap:
- $65.5M
What it means
What to watch
Prepared research question
What matters most for XBIT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XBIT
XBiotech Inc. is a pre-market biopharmaceutical company discovering and developing naturally occurring True Human™ monoclonal antibodies for a variety of diseases, with a pipeline including candidates for rheumatoid arthritis, pancreatic cancer, and other indications.
Key risk: No approved products or revenue
Market Cap
$65.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for XBiotech Inc..
XBiotech Inc. is a pre-market biopharmaceutical company discovering and developing naturally occurring True Human™ monoclonal antibodies for a variety of diseases, with a pipeline including candidates for rheumatoid arthritis, pancreatic cancer, and other indications.
- XBiotech is a pre-market biopharmaceutical company focused on True Human™ monoclonal antibodies, which occur naturally in humans [sec_mda · as of 2026-05-14].
- As of 2026-06-30, the company reported cash & equivalents of $109.5M, shareholders' equity of $128.5M, and a net loss of -$6.7M [sec].
- The company has initiated multiple Phase II trials, including a rheumatoid arthritis study (Natrunix + methotrexate) and a pancreatic cancer study (XB2001 + ONIVYDE) [catalyst].
- An IND application for the V-SPINE (PT064) Phase II study completed FDA review without clinical hold, clearing the path for U.S. patient enrollment as of June 2026 [news · published 2026-06-15].
- The company has an accumulated deficit following the Janssen Transaction in December 2019, tender offer in February 2020, and dividends paid in July 2021 [sec_mda · as of 2026-03-13].
What works
- The company's True Human™ antibody platform is based on naturally occurring monoclonal antibodies, which may offer safety and efficacy advantages over engineered alternatives [sec_mda · as of 2026-05-14].
- XBiotech has a robust cash position of $109.5M as of 2026-06-30, providing runway for ongoing clinical development [sec].
- The company has multiple Phase II trials underway across different therapeutic areas, diversifying its pipeline risk [catalyst].
- Regulatory progress is evident with the FDA clearing the IND for the V-SPINE study without clinical hold, enabling U.S. enrollment [news · published 2026-06-15].
What to weigh
- XBiotech is a pre-market company with no approved products or commercial revenue, relying on future clinical and regulatory success [sec_mda · as of 2026-05-14].
- The company reported a net loss of -$6.7M for the period ending 2026-06-30, reflecting ongoing R&D and operational expenses [sec].
- The accumulated deficit and history of significant transactions (Janssen deal, tender offers) indicate past financial restructuring and dilution risk [sec_mda · as of 2026-03-13].
- Clinical-stage biotech companies face inherent risks of trial failures, regulatory delays, and competition from established therapies.
From the filings
Quoted directly from source documents.
XBiotech is a pre-market biopharmaceutical company developing True Human™ monoclonal antibodies.
“XBiotech Inc. ("XBiotech" or the "Company") is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases.”
SEC MD&A · May 14, 2026
The company's True Human™ antibodies occur naturally in humans, potentially offering safety and efficacy benefits.
“True Human™ monoclonal antibodies are those which occur naturally in human beings--as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts.”
SEC MD&A · May 14, 2026
The IND for the V-SPINE Phase II study cleared FDA review without clinical hold.
“XBiotech Inc. (NASDAQ:XBIT) today announced that its Investigational New Drug (IND) application for V-SPINE (PT064), a Phase II, double-blind, placebo-controlled, randomized study evaluating the efficacy and safety of”
News · June 15, 2026
The company has initiated a Phase II trial of Natrunix in combination with methotrexate for rheumatoid arthritis.
“Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate for the Treatment of Rheumatoid Arthritis”
Catalysts · July 15, 2026
Catalyst timeline
- 2026-07-15 · Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate for the Treatment of Rheumatoid Arthritis — Initiation of a Phase II trial evaluating Natrunix in combination with methotrexate for rheumatoid arthritis.
- 2026-09-01 · Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy and Safety of V-SPINE (PT064) — Initiation of a Phase II study for V-SPINE (PT064) following IND clearance.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — XBiotech is a pre-market company with no commercial products, relying entirely on future clinical success [sec_mda · as of 2026-05-14].
- Clinical trial failure risk — All pipeline candidates are in Phase II or earlier; negative data could significantly impact the company's prospects [catalyst].
- Financial losses and accumulated deficit — The company reported a net loss of -$6.7M as of 2026-06-30 and has an accumulated deficit from prior transactions [sec].
- Dependence on key personnel and financing — The company entered into a convertible loan agreement with its CEO for facility construction, indicating reliance on insider funding [sec_mda · as of 2025-03-18].
What to watch
- Initiation and enrollment progress of the Phase II rheumatoid arthritis trial (Natrunix + methotrexate) [catalyst].
- Initiation and enrollment progress of the Phase II pancreatic cancer trial (XB2001 + ONIVYDE) [catalyst].
- U.S. patient enrollment and data readouts from the V-SPINE (PT064) Phase II study following IND clearance [news · published 2026-06-15].
- Updates on the company's cash runway and any additional financing or partnership activities [sec].
Sources: Catalysts · News · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run XBiotech Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available XBiotech Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 0.8%
- Days to cover
- 3.0
- Shares short
- 144,176
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XBIT short interestGovernance
Frequently asked questions
What is the AI investment thesis for XBiotech Inc.?
XBiotech Inc. is a pre-market biopharmaceutical company discovering and developing naturally occurring True Human™ monoclonal antibodies for a variety of diseases, with a pipeline including candidates for rheumatoid arthritis, pancreatic cancer, and other indications.
Who is the CEO of XBiotech Inc.?
Dr. Sushma Shivaswamy Ph.D. is the chief executive officer of XBiotech Inc. (XBIT).
Where is XBiotech Inc. headquartered?
XBiotech Inc. (XBIT) is headquartered in Austin, TX, United States.
What therapeutic areas does XBiotech Inc. focus on?
XBiotech Inc. develops therapies across Oncology, Immunology, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.